Human CD22 Inhibits Murine B Cell Receptor Activation in a Human CD22 Transgenic Mouse Model

Exploiting CD22 on antigen-specific B cells to prevent allergy to the major peanut allergen Ara h 2

(2017) Kelly A. Orgel et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials

(2017) Megan E. B. Clowse et al.   Arthritis & Rheumatology

CD22 is required for formation of memory B cell precursors within germinal centers

(2017) Craig P. Chappell et al.   PLoS One

Long-Term Safety and Efficacy of Epratuzumab in the Treatment of Moderate-to- Severe Systemic Lupus Erythematosus: Results From an Open-Label Extension Study

(2016) D. J. Wallace et al.   ARTHRITIS CARE & RESEARCH

The mechanistic impact of CD22 engagement with epratuzumab on B cell function: Implications for the treatment of systemic lupus erythematosus

(2015) Thomas Dörner et al.   AUTOIMMUNITY REVIEWS

Nanoscale organization and dynamics of the siglec CD22 cooperate with the cytoskeleton in restraining BCR signalling

(2015) F. Gasparrini et al.   EMBO JOURNAL

Unmasking of CD22 Co-receptor on Germinal Center B-cells Occurs by Alternative Mechanisms in Mouse and Man

(2015) Matthew S. Macauley et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Therapeutic Targeting of Siglecs using Antibody- and Glycan-Based Approaches

(2015) Takashi Angata et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

CD22 and Siglec-G regulate inhibition of B-cell signaling by sialic acid ligand binding and control B-cell tolerance

(2014) L. Nitschke   GLYCOBIOLOGY

CD22 Regulates Time Course of Both B Cell Division and Antibody Response

(2014) T. Onodera et al.   JOURNAL OF IMMUNOLOGY

Siglecs Induce Tolerance to Cell Surface Antigens by BIM-Dependent Deletion of the Antigen-Reactive B Cells

(2014) Matthew S. Macauley et al.   JOURNAL OF IMMUNOLOGY

Transcriptional programs of lymphoid tissue capillary and high endothelium reveal control mechanisms for lymphocyte homing

(2014) Mike Lee et al.   NATURE IMMUNOLOGY

Disubstituted sialic acid ligands targeting siglecs CD33 and CD22 associated with myeloid leukaemias and B cell lymphomas

(2014) Cory D. Rillahan et al.   Chemical Science

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

(2013) Daniel J Wallace et al.   ANNALS OF THE RHEUMATIC DISEASES

A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701

(2013) Barbara W. Grant et al.   CANCER

Antigenic liposomes displaying CD22 ligands induce antigen-specific B cell apoptosis

(2013) Matthew S. Macauley et al.   JOURNAL OF CLINICAL INVESTIGATION

Epratuzumab for Systemic Lupus Erythematosus

(2013) DJ Wallace et al.   LUPUS

Matching cellular dimensions with molecular sizes

(2013) Michael Reth   NATURE IMMUNOLOGY

CD22 ligand-binding and signaling domains reciprocally regulate B-cell Ca2+ signaling

(2013) J. Muller et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006

(2013) V. Strand et al.   RHEUMATOLOGY

Siglecs and Immune Regulation

(2012) Shiv Pillai et al.   Annual Review of Immunology

Human CD22 cannot fully substitute murine CD22 functions in vivo, as shown in a new knockin mouse model

(2012) Miriam Wöhner et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Antigen Delivery to Macrophages Using Liposomal Nanoparticles Targeting Sialoadhesin/CD169

(2012) Weihsu C. Chen et al.   PLoS One

Contribution of Classic and Alternative Effector Pathways in Peanut-Induced Anaphylactic Responses

(2011) Joost J. Smit et al.   PLoS One

In vivo targeting of B-cell lymphoma with glycan ligands of CD22

(2010) W. C. Chen et al.   BLOOD

CD22 x Siglec-G Double-Deficient Mice Have Massively Increased B1 Cell Numbers and Develop Systemic Autoimmunity

(2010) J. Jellusova et al.   JOURNAL OF IMMUNOLOGY

Decoration of T-independent antigen with ligands for CD22 and Siglec-G can suppress immunity and induce B cell tolerance in vivo

(2009) Bao Hoa Duong et al.   JOURNAL OF EXPERIMENTAL MEDICINE